LIPO — LIPELLA PHARMACEUTICALS INC.
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1347242 ·
Last close
$0.10
Market Cap
$462.1K
52W High
$0.19
52W Low
$0.02
ADV30
34,820
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2025 | 0 | -720,973 | -1,274,272 | -1,254,078 | 2,349,810 | 1,855,771 | 862,215 |
| Jun 2025 | 0 | -791,581 | -1,356,575 | -1,327,486 | 3,720,206 | 2,781,828 | 978,534 |
| Mar 2025 | 0 | -993,475 | -1,327,821 | -1,306,523 | 4,856,051 | 4,225,012 | 776,847 |
| Dec 2024 | 173,666 | -888,670 | -1,813,983 | -1,441,672 | 2,673,870 | 2,184,863 | 754,417 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-4,775,737
Investing CF
$0
Financing CF
$5,277,768
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.52
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-19,228,194
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-5,400,340
Pretax Income TTM
$-5,329,759
Interest Exp TTM
$0
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$389,783
EBITDA
$-5,407,074
Free Cash Flow
$-2,827,184
Enterprise Value
$-1,129,603
Total Cash
$1,855,771
Total Debt
$264,083
Shares Out
4,620,837
Trailing EPS
$-2.26
Book Value
$0.32
ROE
-361.8%
ROA
-149.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2024 | 536,357 | -5,080,542 | -5,016,264 | 2,673,870 | 754,417 | — | -3,950,747 |
| Dec 2023 | 449,617 | -4,745,953 | -4,618,965 | 3,577,174 | 432,726 | — | -3,150,172 |
| Dec 2022 | 184,156 | -2,589,713 | -2,597,692 | 5,950,110 | 1,274,514 | — | -1,831,161 |
| Dec 2021 | 259,347 | -1,915,828 | -1,865,473 | 2,012,889 | 589,337 | — | -989,271 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.20
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RGBPP | Regen BioPharma Inc | $523.8K | $0.00 | — |
| PRPH | ProPhase Labs, Inc. | $406.0K | $0.09 | — |
| BPTH | BIO-PATH HOLDINGS, INC. | $345.7K | $0.04 | — |
| VGLS | SB Technology Holdings, Inc. | $316.4K | $0.30 | — |
| EMMA | Emmaus Life Sciences, Inc. | $701.9K | $0.01 | — |
News headlines (Yahoo Finance, 1h cache)
Lipella Pharmaceuticals Inc. Files Voluntary Petitions for Relief Under Chapter 11
2026-03-31 00:20 · Yahoo
Delisting of Securities from The Nasdaq Stock Market
2025-09-24 11:20 · Yahoo
Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing
2025-09-18 12:35 · Yahoo
Lipella Pharmaceuticals Announces Positive Final Results from Phase 2a Study of LP-10 in Oral Lichen Planus
2025-09-18 12:00 · Yahoo
Life Science Virtual Investor Forum Agenda Announced for September 18th
2025-09-16 15:57 · Yahoo
Lipella Pharmaceuticals to Present at Zacks SCR Life Sciences Virtual Investor Forum and Report Final Phase 2a Results in Oral Lichen Planus
2025-09-15 12:00 · Yahoo
Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting
2025-06-25 19:15 · Yahoo
Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market
2025-06-20 19:19 · Yahoo
Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology
2025-06-17 12:30 · Yahoo
Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development
2025-06-04 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.